Aurobindo Pharma's Olanzapine ANDA203708 Receives AP Status from FDA
Aurobindo Pharma's application for olanzapine has received Abbreviated Approval (AP) status from the FDA.
Asset / Drug
Drug and asset intelligence for Olanzapine with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.